Reed Jobs is an instantly likable figure—fast‑talking, self‑deprecating, and peppered with video‑game analogies. Yet his core message is crystal clear: he cares more about curing cancer than capitalising on his father’s legacy.

Founding Vision and Dual‑Funding Model

Launched in 2023, Yosemite is an oncology‑only venture that fuses no‑strings‑attached philanthropy with traditional venture capital to spin out biotech companies from early academic research. Two of the first‑fund’s twenty companies originated directly from grant‑funded labs, underscoring the firm’s belief that early‑stage scientific ideas need risk‑free capital to mature.

AI’s Ascendancy in Biotech

Since the post‑pandemic slump, artificial intelligence has vaulted from a curiosity to a core capability at Yosemite. Jobs explains that AI now powers drug target identification, clinical‑trial design, and even gene‑editing delivery mechanisms—areas where the firm claims a competitive edge. “I didn’t expect Yosemite to be moving this fast,” he admits.

Flagship Portfolio Companies

Azalea, birthed from a grant to Jennifer Doudna’s laboratory, has progressed to clinical trials. Quarry, co‑founded with serial entrepreneur Craig Crews, employs a novel “induced proximity” approach that drags disease‑causing proteins next to the cell’s degradation machinery, rather than attempting direct inhibition.

Funding Landscape and Policy Challenges

Yosemite recently closed the first tranche of its $350 million second fund, allocating roughly one‑third to in‑house spin‑outs and the remainder to external oncology startups. Jobs also warned of historic NIH budget cuts—up to 40 % proposals were rejected by Congress, but a 12 % cut is still on the table—highlighting the need for sustained public investment.

In sum, Yosemite’s rapid expansion, AI‑infused pipeline, and hands‑on company‑building strategy signal a shift toward more agile, founder‑driven cancer therapeutics, challenging the traditional pharmaceutical incumbents.